Gland Pharma reports 97% growth in Q4 FY26 profit after tax

Arunika Jain — Fri, 15 May 2026 11:02:51 +0000

Gland Pharma, an injectable-focused pharmaceutical company, has announced its financial results for the fourth quarter and year ending 31 March 2026, showcasing significant growth in revenue and profitability. The company reported a 22% year-on-year increase in quarterly revenue, reaching ₹17,428 million, and a 97% rise in adjusted profit after tax (PAT) to ₹3,667 million.

Executive Chairman Srinivas Sadu highlighted the company’s strong performance, pointing to a 14.5% growth in consolidated revenue and an adjusted EBITDA margin of 26% for the fiscal year. The growth was driven by robust expansion in the Contract Development and Manufacturing Organisation (CDMO) segment, new product launches, and improved profitability across the existing portfolio.

The company’s gross profit for Q4 FY26 was ₹11,515 million, marking a 23% increase from the previous year, with a consistent gross profit margin of 66%. The adjusted EBITDA for the quarter rose by 51% to ₹5,244 million, with a margin of 30%.

Gland Pharma’s full-year results also showed impressive growth, with total revenue reaching ₹64,307 million, a 14% increase from FY25. The adjusted PAT for the year was ₹10,455 million, representing a 50% rise, while the adjusted EBITDA margin improved to 26%.

The company also announced a final dividend of ₹20 per share, reflecting its strong financial performance and commitment to returning value to shareholders.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Srinivas Sadu | Business Upturn

Gland Pharma reports 97% growth in Q4 FY26 profit after tax